All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Transfusion intensity in patients with JAKi-naive or JAKi-exposed MF treated with momelotinib: A longitudinal assessment
Bookmark this article
|
Momelotinib, a JAK1/2 ACVR1 inhibitor, has shown anemia-related benefits with improved transfusion independence rates in some patients with MF. A post hoc analysis examining longitudinal changes in transfusion intensity with momelotinib in patients with MF using data from phase II and III trials was published in Clinical Lymphoma Myeloma Leukemia by Claire Harrison et al. 1 The analyses included data from a phase II trial (NCT02515630; n = 41) and three phase III trials; SIMPLIFY-1 (NCT01969838; N = 432), SIMPLIFY-2 (NCT02101268; N = 156), and MOMENTUM (NCT04173494; N = 195).1 Patients received 24 weeks of momelotinib treatment in each trial.1 |
| Key learnings |
| Momelotinib provided a consistent anemia benefit for the majority of patients, with ≥77% of patients achieving improved or maintained transfusion intensity compared to baseline data across all four trials. |
|
Momelotinib reduced the mean transfusion requirement by −1.5, −0.1, −0.36, and −0.86 units per 28 days in the phase II and phase III SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials, respectively. 85% of patients achieved a numeric transfusion reduction in the phase II trial. |
| In SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM, momelotinib showed improved or stable transfusion intensities vs ruxolitinib (87% vs 54%), BAT (77% vs 62%), and danazol (85% vs 63%). |
|
In this post hoc analysis, momelotinib was associated with anemia-related benefits in patients with MF compared to comparators. The importance of characterizing anemia-related benefits in MF therapies is highlighted by this novel time-dependent transfusion burden analysis. |
Abbreviations: ACVR1, activin A receptor type 1; BAT, best available therapy, MF, myelofibrosis; RBC, red blood cell; JAKi, Janus kinase inhibitor; TTS, Total Symptom Score.
- Harrison CN, Mesa R, Talpaz M, et al. Longitudinal assessment of transfusion intensity in patients with JAK inhibitor-naive or -experienced myelofibrosis treated with momelotinib. Clin Lymphoma Myeloma Leuk. 2025;25(3):199-211. DOI: 10.1016/j.clml.2024.10.001
Your opinion matters
26 votes - 22 days left ...
Newsletter
Subscribe to get the best content related to MPN delivered to your inbox